Sanofi diabetes drug awaits imminent EU green light

By Ben Hirschler LONDON (Reuters) – Sanofi’s new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday. Toujeo is a more potent follow-up to the French drugmaker’s top-selling Lantus insulin product, which accounts for a fifth of group sales, and the new drug is pivotal to Sanofi’s diabetes business as Lantus faces loss of patent protection. A committee of experts at the European Medicines Agency is considering whether to recommend Toujeo at a regular monthly meeting in London, according to the agency’s website. Assuming Toujeo gets a positive opinion, it is likely to be formally approved by the European Commission a couple of months later, allowing Sanofi to launch in its chosen first European markets of Germany and Britain.
Go to Source